ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 16.42 Delayed Data As of Aug 05 |  +0.80 / +5.12%Today’s Change | 12.24 Today|||52-Week Range 28.06 | -29.65% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $2.7B |
Company Description
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Contact Information
ACADIA Pharmaceuticals, Inc. 12830 El Camino Real San Diego California 92130-3331 |
Employees
Shareholders
| Other institutional | 57.05% |
| Mutual fund holders | 33.92% |
| Individual stakeholders | 32.45% |
Top Executives
| Stephen R. Davis | Chief Executive Officer & Director |
| Srdjan R. Stankovic | President |
| Brendan P. Teehan | Chief Operating Officer, EVP & Head-Commercial |
| Mark C. Schneyer | Chief Financial Officer & Executive Vice President |
| Bob Mischler | Senior VP-Strategy & Technology Operations |
